Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- iptacopan
- voriconazole
Interactions between your drugs
voriconazole iptacopan
Applies to: voriconazole, iptacopan
MONITOR: Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations of voriconazole, which is metabolized by CYP450 2C19, 2C9, and/or 3A4.
MANAGEMENT: The potential for diminished pharmacologic effects of voriconazole should be considered during coadministration with CYP450 inducers. Alternative treatments may be required if an interaction is suspected.
References (1)
- (2002) "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals
Drug and food interactions
voriconazole food
Applies to: voriconazole
ADJUST DOSING INTERVAL: Food reduces the oral absorption and bioavailability of voriconazole. According to the product labeling, administration of multiple doses of voriconazole with high-fat meals decreased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 34% and 24%, respectively, when the drug is administered as a tablet, and by 58% and 37%, respectively, when administered as the oral suspension.
MANAGEMENT: To ensure maximal oral absorption, voriconazole tablets and oral suspension should be taken at least one hour before or after a meal.
References (2)
- (2002) "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Filspari
Filspari is used to slow kidney function decline in adults with primary immunoglobulin A ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Pulmicort Turbuhaler
Pulmicort (budesonide) is used to prevent asthma attacks. Includes Pulmicort side effects ...
Entocort EC
Entocort EC is used to treat active, mild to moderate Crohn's disease (CD) that involves the ileum ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.